[go: up one dir, main page]

MA37777B1 - Préparation pharmaceutique - Google Patents

Préparation pharmaceutique

Info

Publication number
MA37777B1
MA37777B1 MA37777A MA37777A MA37777B1 MA 37777 B1 MA37777 B1 MA 37777B1 MA 37777 A MA37777 A MA 37777A MA 37777 A MA37777 A MA 37777A MA 37777 B1 MA37777 B1 MA 37777B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparation
antibody
high concentration
present
viscosity
Prior art date
Application number
MA37777A
Other languages
English (en)
Other versions
MA20150436A1 (fr
Inventor
Andrew Jeffrey Yates
James Gregory Clipstone
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37777(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MA20150436A1 publication Critical patent/MA20150436A1/fr
Publication of MA37777B1 publication Critical patent/MA37777B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés et des moyens permettant de réduire la viscosité d'une préparation pharmaceutique comprenant un anticorps ou une autre protéine thérapeutique à une concentration élevée. La présente invention concerne une préparation pharmaceutique liquide qui comprend un anticorps à une concentration élevée et présente une viscosité réduite n'empêchant pas le traitement ou l'injection de ladite préparation pharmaceutique.
MA37777A 2012-06-21 2013-06-20 Préparation pharmaceutique MA37777B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21
PCT/EP2013/062898 WO2013190047A1 (fr) 2012-06-21 2013-06-20 Préparation pharmaceutique

Publications (2)

Publication Number Publication Date
MA20150436A1 MA20150436A1 (fr) 2015-11-30
MA37777B1 true MA37777B1 (fr) 2017-07-31

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37777A MA37777B1 (fr) 2012-06-21 2013-06-20 Préparation pharmaceutique

Country Status (25)

Country Link
US (1) US20150150979A1 (fr)
EP (1) EP2864356A1 (fr)
JP (1) JP6157611B2 (fr)
KR (1) KR20150032941A (fr)
CN (1) CN104520326A (fr)
AR (1) AR091530A1 (fr)
AU (1) AU2013279347A1 (fr)
BR (1) BR112014031841A2 (fr)
CA (1) CA2876012A1 (fr)
CL (1) CL2014003283A1 (fr)
CO (1) CO7170174A2 (fr)
EA (1) EA201590061A1 (fr)
EC (1) ECSP15002095A (fr)
HK (1) HK1205146A1 (fr)
IL (1) IL235921A0 (fr)
MA (1) MA37777B1 (fr)
MX (1) MX2014014717A (fr)
NZ (1) NZ702342A (fr)
PE (1) PE20150190A1 (fr)
PH (1) PH12014502596A1 (fr)
SG (1) SG11201407779YA (fr)
TN (1) TN2014000498A1 (fr)
TW (1) TW201406398A (fr)
WO (1) WO2013190047A1 (fr)
ZA (1) ZA201409020B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CN106999510B (zh) 2014-10-01 2021-04-30 伊格尔生物制品有限公司 含有粘度降低剂的多糖和核酸制剂
CA3026426C (fr) * 2016-05-28 2021-04-13 Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Bio-Technology, Government Of India Utroside b et ses derives utilises comme agents therapeutiques pour le carcinome hepatocellulaire
SG11201902531QA (en) * 2016-10-31 2019-05-30 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
EP3569224B1 (fr) * 2017-01-11 2022-12-14 Celltrion Inc. Formule liquide stable
CA3063324A1 (fr) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. Formulations de proteines a haute concentration ayant une viscosite reduite
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
WO2022109052A1 (fr) * 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Formulations de flumazénil pour injection sous-cutanée et méthodes de traitement utilisant des modulateurs du récepteur gaba
EP4247340A4 (fr) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. Formulations salines de composés pharmaceutiques à base d'agents complexants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
PL1610820T5 (pl) * 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
JP2006249083A (ja) * 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 抗ｍ−ｃｓｆ抗体組成物
AR064826A1 (es) * 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
HUE041555T2 (hu) * 2007-06-14 2019-05-28 Biogen Ma Inc Natalizumab antitest készítmények formulációk
WO2011139718A1 (fr) * 2010-05-03 2011-11-10 Genentech, Inc. Compositions et procédés utiles pour la réduction de la viscosité de formulations contenant des protéines
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
SG186421A1 (en) * 2010-07-02 2013-01-30 Medimmune Llc Antibody formulations
EP2694708A4 (fr) * 2011-04-07 2014-10-01 Glaxosmithkline Llc Formulations à viscosité réduite
AU2012250924B2 (en) * 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration

Also Published As

Publication number Publication date
PH12014502596A1 (en) 2015-01-12
ZA201409020B (en) 2016-09-28
TN2014000498A1 (en) 2016-03-30
EP2864356A1 (fr) 2015-04-29
CO7170174A2 (es) 2015-01-28
JP2015520206A (ja) 2015-07-16
MA20150436A1 (fr) 2015-11-30
HK1205146A1 (en) 2015-12-11
CA2876012A1 (fr) 2013-12-27
TW201406398A (zh) 2014-02-16
AU2013279347A1 (en) 2014-12-18
SG11201407779YA (en) 2015-02-27
BR112014031841A2 (pt) 2017-06-27
ECSP15002095A (es) 2015-11-30
PE20150190A1 (es) 2015-02-13
NZ702342A (en) 2016-07-29
CN104520326A (zh) 2015-04-15
JP6157611B2 (ja) 2017-07-05
WO2013190047A1 (fr) 2013-12-27
AR091530A1 (es) 2015-02-11
CL2014003283A1 (es) 2016-04-01
EA201590061A1 (ru) 2015-05-29
KR20150032941A (ko) 2015-03-31
US20150150979A1 (en) 2015-06-04
IL235921A0 (en) 2015-01-29
MX2014014717A (es) 2015-03-06

Similar Documents

Publication Publication Date Title
MA37777B1 (fr) Préparation pharmaceutique
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
MX350010B (es) Inhibidores syk de imidazopiridinas.
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
BR112015025711A8 (pt) uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
BR112013008140A2 (pt) "compostos imidazotriazinona".
MA38986A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
MA39342B2 (fr) Anticorps il -21
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA38190A2 (fr) Inhibiteurs d'autotaxine
FR3061021B1 (fr) Antagoniste specifique de tlr4 dans le traitement du myelome multiple
MA35927B1 (fr) Polythérapie pour le traitement d'un cancer de l'ovaire
Solntseva et al. Individual and combined effects of beta-amyloid1-42, donepezil and haloperidol on long-term potentiation in rat hippocampus
MA38056A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA38625A1 (fr) Procédé pour la préparation d'érythrocytes chargés d'une ou plusieurs substances d'intérêt pharmaceutique, et érythrocytes ainsi obtenus